MK-7655A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $616,649 | 198 | 6 |
| 2017 | $490,474 | 249 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 396 | 96.3% |
| Consulting Fee | $35,625 | 14 | 3.2% |
| Travel and Lodging | $4,775 | 16 | 0.4% |
| Food and Beverage | $719.77 | 21 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial toStudy the Safety, Tolerability, and Efficacy of Imipenem,Cilastatin,Relebactam MK-7655AVersus Piperacillin,Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia orVentilator-Associated Bacterial Pneumonia | Merck Sharp & Dohme Corporation | $594,546 | 0 |
| A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Children from Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections | Merck Sharp & Dohme Corporation | $221,800 | 0 |
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem,Cilastatin,Relebactam MK-7655A Versus Colistimethate Sodium Imipenem,Cilastatin in Subjects with Imipenem-Resistant Bacterial Infection | Merck Sharp & Dohme Corporation | $176,687 | 0 |
| A Randomized, Two-Period, Crossover Study to Examine the Effect of Probenecid on the Pharmacokinetics of Relebactam MK-7655 Administered as MK 7655A 500 mg Imipenem,500 mg Cilastatin,250 mg Relebactam in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $72,971 | 0 |
Top Doctors Receiving Payments for MK-7655A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $1.1M | 396 |
| , M.D | Internal Medicine | Boston, MA | $16,260 | 10 |
| , MD | Infectious Disease | Philadelphia, PA | $8,072 | 9 |
| , MD | Infectious Disease | Philadelphia, PA | $7,768 | 8 |
| , M.D | Internal Medicine | Ann Arbor, MI | $2,275 | 2 |
| , MD | Infectious Disease | Akron, OH | $2,275 | 2 |
| , MD | Pediatric Infectious Diseases | Chapel Hill, NC | $1,875 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Baton Rouge, LA | $994.61 | 8 |
| , M.D | Pediatric Infectious Diseases | Little Rock, AR | $933.17 | 6 |
| , M.D | Pediatrics | Cincinnati, OH | $665.75 | 5 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 9
- Transactions 447
About MK-7655A
MK-7655A is a drug associated with $1.1M in payments to 9 healthcare providers, recorded across 447 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $616,649 was paid across 198 transactions to 6 doctors.
The most common payment nature for MK-7655A is "Unspecified" ($1.1M, 96.3% of total).
MK-7655A is associated with 4 research studies, including "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial toStudy the Safety, Tolerability, and Efficacy of Imipenem,Cilastatin,Relebactam MK-7655AVersus Piperacillin,Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia orVentilator-Associated Bacterial Pneumonia" ($594,546).